FO Nanocomposite / Aquaporin Membrane Patent Landscape
The forward osmosis nanocomposite and aquaporin membrane space is a compact, highly concentrated field dominated by a small cluster of private IP holders, universities, and specialty membrane companies, with the United States as the primary filing jurisdiction. Activity peaked in 2019 and has eased from that high, leaving a field where strategic white space exists in energy-adjacent and biomedical adjacent branches.
Diamond Gold Investors and University of Manchester lead a tightly held field
Diamond Gold Investors LLC holds the top position among the hundred largest filers, followed closely by University of Manchester in second place and ZNANO LLC in third. The top tier is unusually mixed, combining a private IP holding company, two research universities, and specialist membrane firms.
The top five filers account for 42% of the combined patent records of the hundred largest filers — a high concentration ratio for a niche technology, indicating that a handful of entities control the foundational filing positions. A clear tier gap separates the top three from the remaining ranked applicants.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Diamond Gold Investors LLC | 13 | |
| 2 | University of Manchester | 11 | |
| 3 | ZNANO LLC | 7 | |
| 4 | Berghof Membrane Technology GmbH | 4 | |
| 5 | Yale University | 3 | |
| 6 | REVEAU TECH & SOLUTIONS INC | 3 | |
| 7 | Istanbul Technical University | 3 | |
| 8 | Nagare Membranes LLC | 3 | |
| 9 | Kurita Water Industries Ltd. | 3 | |
| 10 | Cornell University | 3 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Kobe University | 3 | |
| 12 | Mauter Meagan S | 2 | |
| 13 | Vantive Health GmbH | 2 | |
| 14 | National Institute of Technology Calicut | 2 | |
| 15 | Aquaporin Asia Pte Ltd. | 2 | |
| 16 | Vantive US Healthcare LLC | 2 | |
| 17 | Giannelis Emmanuel P | 2 | |
| 18 | CrossTek Holding Co. LLC | 2 | |
| 19 | Xi’an University of Architecture and Technology | 2 | |
| 20 | Qatar University | 2 |
Diamond Gold Investors LLC’s leading position, combined with University of Manchester’s strong academic output and ZNANO LLC’s specialist focus, suggests that core platform IP sits partly outside traditional industrial incumbents — a signal that licensing exposure or freedom-to-operate risk may be distributed across non-practicing entities and academic spinouts.
The most recent filing years are subject to publication lag and should be treated as incomplete; apparent softness in 2024–2026 data does not necessarily reflect true filing activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2019 filing peak with separation processes dominating the technology mix
Annual filing volume and the IPC technology composition together reveal both the maturity of the field and the technical directions that have attracted the most attention.
Annual filing trend
Filings surged to a peak in 2019 with 12 records that year, then eased back through 2021–2022, before a secondary uptick in 2023. Data for 2024–2026 is incomplete due to publication lag and should not be read as a sustained decline. The 2019 peak marks the field’s most active single year.
↗ Hover for values · click a bar to ask EurekaTechnology composition
B01D (Separation processes including filtration) dominates the IPC composition by a wide margin, reflecting the membrane engineering core of this technology. C02F (Water and wastewater treatment) is the second largest branch, confirming water purification as the primary application domain. Smaller shares appear in H01M (Batteries and fuel cells), B32B (Layered products), A61M (Devices for body fluids), and several polymer and nanomaterial classes, indicating early-stage diversification beyond water treatment.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Reduced graphene oxide forward osmosis membranes, …
One aspect of the invention relates to a forward osmosis (FO) membrane including a selectively permeable active layer formed of a graphene-based material with tunable interlayer spacing; and a support membrane providing mechanical stability. The FO membrane enhances water flux while minimizing reverse solute flux. (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | A forward osmosis membrane | 109 |
| 2 | Nanoparticle-functionalized membranes, methods of … | 44 |
| 3 | Nanoparticle-functionalized membranes, methods of … | 25 |
| 4 | osmosis | 22 |
| 5 | osmosis | 20 |
| 6 | Membranes for forward osmosis and membrane distill… | 19 |
| 7 | Methods for reducing ion exchange and reverse salt… | 15 |
| 8 | Membranes for forward osmosis and membrane distill… | 12 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for R&D investment decisions
The combination of post-peak filing volume, high concentration, active academic–industrial collaboration, and a dominant US–PCT–European jurisdictional footprint shapes the risk and opportunity profile for new entrants and incumbents alike.
Post-peak field with eased annual volume
The lifecycle stage is classified as Decline, with annual filings easing back from the 2019 peak. This does not mean the technology is obsolete — it more likely reflects consolidation of core platform IP and a shift toward application-specific development. New entrants should expect a mature claim landscape in the central separation-process space and look to adjacent branches for differentiated filing positions.
Post-peak · 2019 peak yearTop five control 42% of ranked filer records
The top five applicants — Diamond Gold Investors LLC, University of Manchester, ZNANO LLC, Berghof Membrane Technology GmbH, and Yale University — hold 42% of patent records among the hundred largest filers. This level of concentration in a 42-family corpus means that core platform claims are tightly held. Any commercial development strategy should include a freedom-to-operate analysis against the Diamond Gold Investors and University of Manchester portfolios in particular.
High concentrationThree active co-filing pairs anchor the ecosystem
The most active co-applicant pair is Baxter International Inc. and Baxter Healthcare SA, which have co-filed 4 records, reflecting a coordinated corporate IP strategy across legal entities. Kurita Water Industries Ltd. and Kobe University have co-filed 3 records, linking industrial water treatment expertise with academic membrane science. Aquaporin A/S and Aquaporin Asia Pte Ltd. have co-filed 2 records, indicating coordinated international IP deployment. These pairings define the primary industry–academia collaboration axes in the field.
Corporate + academic pairsUS-led, with PCT and European coverage reflecting commercialization intent
The United States leads jurisdiction coverage with 21 patent records, followed by WIPO PCT filings with 14 and Europe (EPO) with 10. India and China each show 10 and 9 records respectively, suggesting awareness of emerging-market water treatment demand. Denmark (3 records) is notable given Aquaporin A/S’s home jurisdiction. The breadth of PCT and EPO coverage relative to the small total corpus indicates that leading filers are pursuing broad international protection on a targeted basis.
US · PCT · EP coreGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Baxter International Inc. | Baxter Healthcare SA | 4 |
| Kurita Water Industries Ltd. | Kobe University | 3 |
| Aquaporin A/S | Aquaporin Asia Pte Ltd. | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Diamond Gold Investors and University of Manchester define the leading positions
The top two filers differ in character — one is a private IP holding entity, the other an academic institution — but both concentrate their records squarely in B01D separation process subclasses, the technical core of FO nanocomposite and aquaporin membrane development.
Diamond Gold Investors LLC
Diamond Gold Investors LLC leads the ranked filers with 13 patent records, all concentrated in B01D separation process subclasses (B01D 69, B01D 71, B01D 61). As a private IP holding company rather than an operating manufacturer, its portfolio represents a licensing and enforcement asset. No recent-period momentum data is available for this entity from the evidence, so trajectory cannot be characterized.
13 patent recordsUniversity of Manchester
University of Manchester holds 11 patent records, equally distributed across B01D 61, B01D 69, and B01D 71 subclasses, indicating broad membrane fabrication and process coverage. As an academic institution, its filings likely underpin licensing agreements with industrial partners. Aquaporin A/S is classified as a new entrant in the most recent filing window with 5 recent records, making it the fastest-rising entity in the current period and a company to watch for commercialization momentum.
11 patent records| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Aquaporin A/S | 5 | ▲ new entrant |
| Baxter International Inc. | 1 | ▲ new entrant |
| Baxter Healthcare SA | 1 | ▲ new entrant |
Under-served branches adjacent to the separation-process core
Several IPC branches appear in the corpus at low share levels, representing areas where FO nanocomposite and aquaporin membrane technology has been applied or could plausibly extend, but where the filing density remains sparse relative to the B01D core.
H01M · Batteries, cells & fuel cells
H01M accounts for 8 patent records at 5% of the IPC distribution — the largest of the adjacent branches. Aquaporin-inspired proton-selective membranes and nanocomposite separators for fuel cells represent a technically plausible extension of forward osmosis membrane design principles. The low filing count suggests this intersection is not yet systematically claimed, and an entrant with both membrane fabrication and electrochemical expertise could find differentiated filing positions here.
Search this in Eureka →A61M · Devices for body fluids
A61M covers devices for managing body fluids, including dialysis and blood filtration — an application where aquaporin water channels have clear biological relevance. Only 4 patent records appear under this class, representing 2% of the IPC distribution. Baxter International’s collaboration filings already touch this space, but the overall filing density remains low. The regulatory and biocompatibility requirements raise the entry bar, but also reduce the likelihood of rapid crowding from non-specialist entrants.
Search this in Eureka →Frequently asked questions
The evidence covers 42 patent families in scope for this technology area, spanning global filings across multiple jurisdictions including the United States, WIPO PCT, Europe, India, and China.
Diamond Gold Investors LLC leads with 13 patent records among the top 100 ranked filers, followed by University of Manchester with 11 and ZNANO LLC with 7. Diamond Gold Investors is a private IP holding company, not an operating membrane manufacturer.
Annual filing activity peaked in 2019 with 12 records that year. Volume eased through 2020–2022 before a secondary uptick in 2023. The lifecycle stage is classified as Decline, meaning annual volume has eased from the 2019 peak. Data for 2024 and 2025 is incomplete due to publication lag.
The United States leads with 21 patent records, followed by WIPO PCT with 14 records and Europe (EPO) and India each with 10 records. China shows 9 records. The PCT and EPO coverage relative to the small corpus total indicates that leading filers are pursuing broad international protection.
B01D (Separation processes including filtration) dominates by a wide margin, confirming membrane engineering as the technical core. C02F (Water and wastewater treatment) is the second largest class. Adjacent branches including H01M (Batteries and fuel cells) and A61M (Devices for body fluids) each appear at low share levels.
Yes. Three co-filing pairs are identified in the evidence: Baxter International Inc. and Baxter Healthcare SA (4 co-filed records), Kurita Water Industries Ltd. and Kobe University (3 co-filed records), and Aquaporin A/S and Aquaporin Asia Pte Ltd. (2 co-filed records). These pairs represent the primary collaboration axes in the field.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.